Monte Rosa Therapeutics, Inc.
GLUENASDAQHealthcare● Active
$16.83
+$0.46(+2.78%)
Market Cap$1.1B
P/E Ratio—
52W High$25.77
52W Low$4.12
Monte Rosa Therapeutics, Inc. (GLUE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GLUE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.45
Est. -$0.28 · -60.7%
Revenue
$0.00B
Est. $0.01B · -61.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
GLUE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.37 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.28 | -$0.45 | -60.7% | $0.00B | $0.01B | -61.6% |
| ▼ Q1 FY2026 | Mar 17, 2026 | -$0.35 | -$0.54 | -53.6% | $0.00B | $0.02B | -82.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.37 | -$0.33 | +9.9% | $0.01B | $0.02B | -17.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.38 | -$0.15 | +60.2% | $0.02B | $0.01B | +198.4% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.00 | $0.57 | +21690.9% | $0.08B | $0.01B | +526.0% |
| ▲ Q1 FY2025 | Mar 20, 2025 | $0.02 | $0.23 | +1379.1% | $0.06B | $0.05B | +29.9% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.49 | -$0.29 | +40.8% | $0.01B | $0.00B | +249.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.37
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.45
EPS Est.
-$0.28
EPS Surpr.
-60.7%
Revenue
$0.00B
Q1 FY2026
Mar 17, 2026Miss
EPS Actual
-$0.54
EPS Est.
-$0.35
EPS Surpr.
-53.6%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.37
EPS Surpr.
+9.9%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.38
EPS Surpr.
+60.2%
Revenue
$0.02B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$0.57
EPS Est.
-$0.00
EPS Surpr.
+21690.9%
Revenue
$0.08B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
$0.23
EPS Est.
$0.02
EPS Surpr.
+1379.1%
Revenue
$0.06B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.29
EPS Est.
-$0.49
EPS Surpr.
+40.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.80 | $-0.67 | $0.04 | 1 |
| Q3 FY2027 | $-1.73 | $-0.64 | $0.03 | 1 |
| Q2 FY2027 | $-1.72 | $-0.64 | $0.03 | 1 |
| Q1 FY2027 | $-1.60 | $-0.59 | $0.03 | 1 |
| Q4 FY2026 | $-1.16 | $-0.43 | $0.02 | 1 |
| Q3 FY2026 | $-0.77 | $-0.40 | $0.18 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -60.7% | $20.39 | $19.81 | -2.84% |
| ▼ Q1 FY2026 | Mar 17, 2026 | -53.6% | $16.35 | $16.03 | -1.96% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +9.9% | $12.31 | $13.01 | +5.69% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +60.2% | $4.36 | $4.23 | -2.98% |
| ▲ Q2 FY2025 | May 8, 2025 | +21690.9% | $3.85 | $4.22 | +9.61% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +1379.1% | $6.70 | $7.06 | +5.37% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +40.8% | $9.45 | $9.53 | +0.85% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +20.4% | $3.61 | $3.98 | +10.25% |
Q2 FY2026-2.84%
Report Date
May 7, 2026
EPS Beat/Miss
-60.7%
Price Before
$20.39
Price After
$19.81
Q1 FY2026-1.96%
Report Date
Mar 17, 2026
EPS Beat/Miss
-53.6%
Price Before
$16.35
Price After
$16.03
Q4 FY2025+5.69%
Report Date
Nov 6, 2025
EPS Beat/Miss
+9.9%
Price Before
$12.31
Price After
$13.01
Q3 FY2025-2.98%
Report Date
Aug 7, 2025
EPS Beat/Miss
+60.2%
Price Before
$4.36
Price After
$4.23
Q2 FY2025+9.61%
Report Date
May 8, 2025
EPS Beat/Miss
+21690.9%
Price Before
$3.85
Price After
$4.22
Q1 FY2025+5.37%
Report Date
Mar 20, 2025
EPS Beat/Miss
+1379.1%
Price Before
$6.70
Price After
$7.06
Q4 FY2024+0.85%
Report Date
Nov 7, 2024
EPS Beat/Miss
+40.8%
Price Before
$9.45
Price After
$9.53
Q3 FY2024+10.25%
Report Date
Aug 8, 2024
EPS Beat/Miss
+20.4%
Price Before
$3.61
Price After
$3.98
Avg Beat Reaction+4.80%
Avg Miss Reaction-2.40%
Beat Rate6 / 8 quarters
Largest Move+10.25% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GLUE ends December
Monte Rosa Therapeutics, Inc. (GLUE) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.45 — missing the analyst consensus of $-0.28 by -60.7%. The next GLUE earnings date is expected around September 1, 2026.
Each quarter, investors track GLUE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GLUE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GLUE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GLUE earnings · 5 questionsMonte Rosa Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. GLUE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GLUE historically reports after market close (AMC).
GLUE earnings datewhen is GLUE earningsGLUE next earnings datewhen does GLUE report earningsGLUE earnings calendar
▸ Source: FMP · Monte Rosa Therapeutics, Inc. SEC filings · US GAAP · Monte Rosa Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026